- Home
- TRMD vs AKRO Comparison
TRMD vs AKRO Comparison
Compare TRMD & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- AKRO
- Stock Information
- Founded
- TRMD 1889
- AKRO 2017
- Country
- TRMD United Kingdom
- AKRO United States
- Employees
- TRMD N/A
- AKRO N/A
- Industry
- TRMD Marine Transportation
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- TRMD Consumer Discretionary
- AKRO Health Care
- Exchange
- TRMD Nasdaq
- AKRO Nasdaq
- Market Cap
- TRMD 1.9B
- AKRO 2.0B
- IPO Year
- TRMD N/A
- AKRO 2019
- Fundamental
- Price
- TRMD $19.30
- AKRO $28.74
- Analyst Decision
- TRMD Buy
- AKRO Strong Buy
- Analyst Count
- TRMD 1
- AKRO 8
- Target Price
- TRMD $48.00
- AKRO $46.83
- AVG Volume (30 Days)
- TRMD 1.2M
- AKRO 596.7K
- Earning Date
- TRMD 11-07-2024
- AKRO 11-08-2024
- Dividend Yield
- TRMD 24.41%
- AKRO N/A
- EPS Growth
- TRMD N/A
- AKRO N/A
- EPS
- TRMD 7.70
- AKRO N/A
- Revenue
- TRMD $1,641,593,000.00
- AKRO N/A
- Revenue This Year
- TRMD N/A
- AKRO N/A
- Revenue Next Year
- TRMD N/A
- AKRO N/A
- P/E Ratio
- TRMD $2.53
- AKRO N/A
- Revenue Growth
- TRMD 3.90
- AKRO N/A
- 52 Week Low
- TRMD $17.77
- AKRO $15.32
- 52 Week High
- TRMD $40.47
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- TRMD 40.05
- AKRO 41.05
- Support Level
- TRMD $17.77
- AKRO $27.80
- Resistance Level
- TRMD $19.76
- AKRO $29.79
- Average True Range (ATR)
- TRMD 0.53
- AKRO 1.50
- MACD
- TRMD 0.29
- AKRO -0.20
- Stochastic Oscillator
- TRMD 64.44
- AKRO 16.39
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Exhaust segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.